BioTalk

Companies in the life sciences sector and its sub-sectors, including pharmaceuticals, medical devices, diagnostics and services, are...

There is a huge cost of bringing a pharmaceutical product to market, with estimates ranging from US$1-2 billion to take a product from...

This article is part of our series covering the proposed reforms to the EU pharmaceutical legislation. To view the entire series, click...

In recent decades, venture capital (VC) has played an increasingly important role in the high-risk and high-reward life sciences sector....

The CJEU brings clarity, on the concepts of “Significant Benefit” and “Clinical Superiority” with respect to Orphan Medicinal Products...

In the rapidly evolving world of life sciences, merger control and foreign direct investment (“FDI”) regimes have emerged as key...

On September 12, 2024, the Court of Justice of the European Union (CJEU) delivered a ruling in a case involving Novo Nordisk AS...

The life sciences sector, comprising of sub-sectors like pharmaceuticals, medical devices, diagnostics and services, aims to cure disease...

This article is part of our series covering the proposed reforms to the EU pharmaceutical legislation. To view the entire series, click...

On 18 July 2024 President Von der Leyen laid down the path for the next European Commission in her Political Guidelines for the next...

Earlier this summer, the Irish Pharmaceutical Healthcare Association (IPHA), which represents the international originator...